{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:13:20Z","timestamp":1788869600387,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002848","name":"CONICYT REGIONAL \/ GORE MAULE \/ CEAP \/ R09I2001","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002848","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Programa de Investigaci\u00f3n de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES)"},{"name":"Fondecyt, Chile","award":["1130216"],"award-info":[{"award-number":["1130216"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.thromres.2014.04.027","type":"journal-article","created":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T23:45:14Z","timestamp":1398987914000},"page":"221-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk"],"prefix":"10.1016","volume":"134","author":[{"given":"Eduardo","family":"Fuentes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.04.027_bb0005","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/01.CIR.0000086897.15588.4B","article-title":"Cardiology patient page Platelets and cardiovascular disease","volume":"108","author":"Gregg","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.04.027_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-5273(97)00203-9","article-title":"Smoking and lipoprotein abnormalities on platelet aggregation in coronary heart disease","volume":"62","author":"de Padua","year":"1997","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0015","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/00004872-199210120-00003","article-title":"Platelet aggregation in spontaneous hypertension: genetic determination and correlation analysis","volume":"10","author":"Pravenec","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.thromres.2014.04.027_bb0020","first-page":"39","article-title":"Hypercholesterolaemia accentuates platelet activity","volume":"11","author":"Lane","year":"1986","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.thromres.2014.04.027_bb0025","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/01.ATV.0000095974.95122.EC","article-title":"Platelets in inflammation and thrombosis","volume":"23","author":"Wagner","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0030","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2011-09-377648","article-title":"Platelet TGF-beta1 contributions to plasma TGF-beta1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload","volume":"119","author":"Meyer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.04.027_bb0035","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/ATVBAHA.113.302700","article-title":"Interleukin 1 receptor 1 and interleukin 1beta regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans","volume":"34","author":"Beaulieu","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3132\/dvdr.2005.014","article-title":"Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products","volume":"2","author":"Varo","year":"2005","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.thromres.2014.04.027_bb0045","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/01.CIR.103.13.1772","article-title":"RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium","volume":"103","author":"von Hundelshausen","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.04.027_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd966","article-title":"Antithrombotic drug market","volume":"2","author":"Collins","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.thromres.2014.04.027_bb0055","first-page":"179","article-title":"The role of platelets in the pathophysiology of atherosclerosis (Review)","volume":"1","author":"Palomo","year":"2008","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.thromres.2014.04.027_bb0060","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-4-44","article-title":"Novel agents for anti-platelet therapy","volume":"4","author":"Ji","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0065","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/bjp.2008.151","article-title":"Future innovations in anti-platelet therapies","volume":"154","author":"Barrett","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/HCO.0b013e328356ae95","article-title":"The aspirin controversy in primary prevention","volume":"27","author":"Raju","year":"2012","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.04.027_bb0080","doi-asserted-by":"crossref","first-page":"300S","DOI":"10.1378\/chest.119.1_suppl.300S","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke","volume":"119","author":"Albers","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.04.027_bb0085","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0741-5214(03)01029-2","article-title":"Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time","volume":"38","author":"Wilhite","year":"2003","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.thromres.2014.04.027_bb0090","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1161\/hs1201.100829","article-title":"Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients?","volume":"32","author":"Albers","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2014.04.027_bb0095","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.04.027_bb0100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2217\/14796678.2.3.343","article-title":"Antiplatelet therapy: current strategies and future trends","volume":"2","author":"Tantry","year":"2006","journal-title":"Future Cardiol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCINTERVENTIONS.111.967208","volume":"5","author":"Mahla","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.thromres.2014.04.027_bb0110","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0021-9258(19)75924-9","article-title":"Agents that elevate cAMP levels in platelets decrease thrombin binding","volume":"262","author":"Lerea","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0115","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1073\/pnas.84.16.5620","article-title":"Agents that elevate the concentration of cAMP in platelets inhibit the formation of a NaDodSO4-resistant complex between thrombin and a 40-kDa protein","volume":"84","author":"Lerea","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thromres.2014.04.027_bb0120","series-title":"Hematolog\u00eda: Fisiopatolog\u00eda y Diagn\u00f3stico","first-page":"459","article-title":"Hemostasia Primaria","author":"Santos","year":"2005"},{"key":"10.1016\/j.thromres.2014.04.027_bb0125","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJMra0801082","article-title":"Mechanisms of thrombus formation","volume":"359","author":"Furie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.04.027_bb0130","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1182\/blood-2006-12-027698","article-title":"The growing complexity of platelet aggregation","volume":"109","author":"Jackson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.04.027_bb0135","doi-asserted-by":"crossref","unstructured":"Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol.30:2341-9.","DOI":"10.1161\/ATVBAHA.110.207522"},{"key":"10.1016\/j.thromres.2014.04.027_bb0140","doi-asserted-by":"crossref","first-page":"30725","DOI":"10.1074\/jbc.M301838200","article-title":"Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0145","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein-coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.thromres.2014.04.027_bb0150","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1161\/01.CIR.99.19.2499","article-title":"Caffeine alters A2A adenosine receptors and their function in human platelets","volume":"99","author":"Varani","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.04.027_bb0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrd2957","article-title":"Antiplatelet therapies for the treatment of cardiovascular disease","volume":"9","author":"Michelson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.thromres.2014.04.027_bb0160","doi-asserted-by":"crossref","first-page":"29321","DOI":"10.1074\/jbc.M111390200","article-title":"Development of platelet inhibition by cAMP during megakaryocytopoiesis","volume":"277","author":"den Dekker","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0165","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood-2006-10-052522","article-title":"Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation\/activation of phosphodiesterase 3A","volume":"110","author":"Zhang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.04.027_bb0170","doi-asserted-by":"crossref","first-page":"15666","DOI":"10.1074\/jbc.M009217200","article-title":"Cyclic nucleotides modulate store-mediated calcium entry through the activation of protein-tyrosine phosphatases and altered actin polymerization in human platelets","volume":"276","author":"Rosado","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0175","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2004-03-1058","article-title":"Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide","volume":"104","author":"Jensen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.04.027_bb0180","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.bcp.2003.12.028","article-title":"Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3","volume":"67","author":"Feijge","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0185","doi-asserted-by":"crossref","first-page":"e51037","DOI":"10.1371\/journal.pone.0051037","article-title":"The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)\/G(i)-dependent mechanism","volume":"7","author":"Xiang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2014.04.027_bb0190","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1160\/TH08-12-0781","article-title":"Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets","volume":"102","author":"Hayashi","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/382083a0","article-title":"Regulation by cAMP-dependent protein kinease of a G-protein-mediated phospholipase C","volume":"382","author":"Liu","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2014.04.027_bb0200","doi-asserted-by":"crossref","first-page":"47080","DOI":"10.1074\/jbc.M208329200","article-title":"Regulation of glycoprotein Ib-IX-von Willebrand factor interaction by cAMP-dependent protein kinase-mediated phosphorylation at Ser 166 of glycoprotein Ib(beta)","volume":"277","author":"Bodnar","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0205","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1182\/blood-2002-10-3210","article-title":"A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans","volume":"101","author":"Li","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.04.027_bb0210","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0006-2952(00)00452-4","article-title":"Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand\/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets","volume":"60","author":"Schwarz","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0215","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1055\/s-0037-1613448","article-title":"Differential regulation of P-selectin expression by protein kinase A and protein kinase G in thrombin-stimulated human platelets","volume":"89","author":"Libersan","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0220","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1527-3466.1993.tb00200.x","article-title":"Cilostazol","volume":"11","author":"Okuda","year":"1993","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.thromres.2014.04.027_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosissup.2005.09.002","article-title":"Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding","volume":"6","author":"Goto","year":"2005","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.thromres.2014.04.027_bb0230","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ahj.2004.03.066","article-title":"Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials","volume":"148","author":"Schleinitz","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2014.04.027_bb0235","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0022-3565(24)37806-1","article-title":"Depletion of protein kinase C-alpha by antisense oligonucleotides alters beta-adrenergic function and reverses the phorbol ester-induced reduction of isoproterenol-induced adenosine 3'-5'-cyclic monophosphate accumulation in murine Swiss 3T3 fibroblasts","volume":"287","author":"Levesque","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.thromres.2014.04.027_bb0240","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/ATVBAHA.109.193367","article-title":"PPARbeta\/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association\/repression of PKCalpha\u2013brief report","volume":"29","author":"Ali","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0245","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","article-title":"P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries","volume":"112","author":"Andre","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2014.04.027_bb0250","doi-asserted-by":"crossref","first-page":"29108","DOI":"10.1074\/jbc.274.41.29108","article-title":"Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors","volume":"274","author":"Paul","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0255","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2009.06.029","article-title":"Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis\/hemostasis","volume":"124","author":"van Giezen","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.04.027_bb0260","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3109\/09537104.2011.576284","article-title":"P2Y(1)(2) and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP","volume":"22","author":"Iyu","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2014.04.027_bb0265","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1160\/TH10-07-0482","article-title":"Mode of action of P2Y(12) antagonists as inhibitors of platelet function","volume":"105","author":"Iyu","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0270","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.biocel.2003.08.006","article-title":"Prostanoids and prostanoid receptors in signal transduction","volume":"36","author":"Bos","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0275","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature10136","article-title":"Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation","volume":"474","author":"Lebon","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2014.04.027_bb0280","doi-asserted-by":"crossref","first-page":"e90699","DOI":"10.1371\/journal.pone.0090699","article-title":"Chlorogenic Acid Inhibits Human Platelet Activation and Thrombus Formation","volume":"9","author":"Fuentes","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2014.04.027_bb0285","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH13-05-0386","article-title":"Protective mechanisms of adenosine 5'-monophosphate in platelet activation and thrombus formation","volume":"111","author":"Fuentes","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0290","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4155\/fmc.13.127","article-title":"Therapeutic potential of PDE modulation in treating heart disease","volume":"5","author":"Knight","year":"2013","journal-title":"Future Med Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.thromres.2014.04.027_bb0300","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1055\/s-0037-1613099","article-title":"Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases","volume":"87","author":"Manns","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0305","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00005344-199910000-00004","article-title":"Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells","volume":"34","author":"Cone","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0310","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0315","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.pharmthera.2005.08.007","article-title":"Peroxisome proliferator-activated receptors and inflammation","volume":"110","author":"Moraes","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.04.027_bb0320","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2796.2007.01825.x","article-title":"PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?","volume":"262","author":"Ahmed","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.thromres.2014.04.027_bb0325","doi-asserted-by":"crossref","first-page":"136584","DOI":"10.1155\/2013\/136584","article-title":"Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome","volume":"2013","author":"Fuentes","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.thromres.2014.04.027_bb0330","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3892\/mmr.2013.1714","article-title":"Role of PPARs in inflammatory processes associated with metabolic syndrome (Review)","volume":"8","author":"Fuentes","year":"2013","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.thromres.2014.04.027_bb0335","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/174182670100800402","article-title":"PPARS in inflammation, atherosclerosis and thrombosis","volume":"8","author":"Duez","year":"2001","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.thromres.2014.04.027_bb0340","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/35013000","article-title":"Roles of PPARs in health and disease","volume":"405","author":"Kersten","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2014.04.027_bb0345","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neulet.2003.09.001","article-title":"Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice","volume":"352","author":"Inoue","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.thromres.2014.04.027_bb0350","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1161\/01.CIR.0000147614.85888.7A","article-title":"Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice","volume":"110","author":"Verreth","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.04.027_bb0355","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1471-4914(02)02385-7","article-title":"The role of PPARs in atherosclerosis","volume":"8","author":"Duval","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.thromres.2014.04.027_bb0360","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1073\/pnas.0711875105","article-title":"PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis","volume":"105","author":"Barish","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thromres.2014.04.027_bb0365","doi-asserted-by":"crossref","first-page":"15924","DOI":"10.1073\/pnas.0306981100","article-title":"Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome","volume":"100","author":"Tanaka","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thromres.2014.04.027_bb0370","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2004-03-0926","article-title":"Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes","volume":"104","author":"Akbiyik","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.04.027_bb0375","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00063030-200620040-00004","article-title":"Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease","volume":"20","author":"Ray","year":"2006","journal-title":"BioDrugs"},{"key":"10.1016\/j.thromres.2014.04.027_bb0380","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1538-7836.2010.03769.x","article-title":"A new role for the A2b adenosine receptor in regulating platelet function","volume":"8","author":"Yang","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0385","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/ATVBAHA.111.241067","article-title":"Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity","volume":"32","author":"Loyau","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0390","first-page":"695","article-title":"cAMP regulates ADP-induced HSP27 phosphorylation in human platelets","volume":"27","author":"Enomoto","year":"2011","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.thromres.2014.04.027_bb0395","article-title":"Mechanism of the anti-platelet effect of natural bioactive compounds: Role of peroxisome proliferator-activated receptors activation","author":"Fuentes","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2014.04.027_bb0400","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0405","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1423-0127-17-45","article-title":"Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation","volume":"17","author":"Lee","year":"2010","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.thromres.2014.04.027_bb0410","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/bjp.2008.19","article-title":"Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin","volume":"153","author":"Chou","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0415","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0037-1615646","article-title":"Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation","volume":"85","author":"Berckmans","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0420","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0021-9150(95)05551-7","article-title":"Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus","volume":"116","author":"Nomura","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2014.04.027_bb0425","first-page":"110","article-title":"Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells indicating protection against cell activation","author":"Suades","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0430","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1160\/TH10-12-0810","article-title":"Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease","volume":"106","author":"Mobarrez","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0435","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.2337\/diabetes.47.9.1494","article-title":"Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism","volume":"47","author":"Ishizuka","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.thromres.2014.04.027_bb0440","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1161\/01.CIR.0000074043.46437.44","article-title":"Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones","volume":"107","author":"Varo","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.04.027_bb0445","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.0000069272.06194.91","article-title":"Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease","volume":"107","author":"Marx","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.04.027_bb0450","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1074\/jbc.M208132200","article-title":"Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes","volume":"278","author":"Dello Russo","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0455","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.04.027_bb0460","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00542324","article-title":"Effects of treatment with nifedipine and metoprolol in essential hypertension","volume":"21","author":"Eggertsen","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0465","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/01.CIR.92.5.1074","article-title":"Nifedipine in ischemic heart disease","volume":"92","author":"Kloner","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.04.027_bb0470","doi-asserted-by":"crossref","unstructured":"Shih CY, Lin MH, Fan HC, Chen FC, Chou TC. Mechanisms of antiplatelet activity of nifedipine: role of peroxisome proliferator-activated receptor-beta-gamma-dependent processes. J Hypertens.32:181-92.","DOI":"10.1097\/HJH.0000000000000007"},{"key":"10.1016\/j.thromres.2014.04.027_bb0475","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","article-title":"Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism","volume":"11","author":"Nylander","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0480","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1055\/s-0038-1665327","article-title":"Dipyridamole inhibits platelet aggregation in whole blood","volume":"50","author":"Gresele","year":"1983","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0485","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.thromres.2006.05.005","article-title":"Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation","volume":"119","author":"Nakamura","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.04.027_bb0490","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/01.STR.15.2.241","article-title":"Prolongation of bleeding time and inhibition of platelet aggregation by low-dose acetylsalicylic acid in patients with cerebrovascular disease","volume":"15","author":"Boysen","year":"1984","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2014.04.027_bb0495","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd1198","article-title":"Antiplatelet therapy: in search of the 'magic bullet'","volume":"2","author":"Jackson","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.thromres.2014.04.027_bb0500","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1160\/TH11-06-0400","article-title":"BF061, a novel antiplatelet and antithrombotic agent targeting P2Y(1)(2) receptor and phosphodiesterase","volume":"106","author":"Hu","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0505","doi-asserted-by":"crossref","first-page":"e40451","DOI":"10.1371\/journal.pone.0040451","article-title":"BF066, a novel dual target antiplatelet agent without significant bleeding","volume":"7","author":"Pan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2014.04.027_bb0510","first-page":"269","article-title":"Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus","volume":"29","author":"Tamai","year":"1999","journal-title":"Haemostasis"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2014.04.027_bb0515","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1463-1326.2002.0040s2s14.x","article-title":"The pharmacology of cilostazol","volume":"4","author":"Schror","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.thromres.2014.04.027_bb0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosissup.2005.09.005","article-title":"Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination","volume":"6","author":"Comerota","year":"2005","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.thromres.2014.04.027_bb0525","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","article-title":"Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake","volume":"19","author":"Liu","year":"2001","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.thromres.2014.04.027_bb0530","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/09537109975933","article-title":"Inhibitory effect of Ginkgo biloba extract on human platelet aggregation","volume":"10","author":"Dutta-Roy","year":"1999","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2014.04.027_bb0535","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.thromres.2009.02.010","article-title":"Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time","volume":"124","author":"Ryu","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.04.027_bb0540","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation","volume":"7","author":"JJ","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0545","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.04.027_bb0550","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005344-200408000-00017","article-title":"Cilostazol and dipyridamole synergistically inhibit human platelet aggregation","volume":"44","author":"Liu","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.thromres.2014.04.027_bb0555","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-005-6896-0","article-title":"Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation","volume":"19","author":"Li","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.thromres.2014.04.027_bb0560","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.04.027_bb0565","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets I Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2014.04.027_bb0570","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1172\/JCI111705","article-title":"Functionally thrombasthenic state in normal platelets following the administration of ticlopidine","volume":"75","author":"Di Minno","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2014.04.027_bb0575","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.thromres.2014.04.027_bb0580","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.04.027_bb0585","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/bbrc.2001.4816","article-title":"P2y(12), a new platelet ADP receptor, target of clopidogrel","volume":"283","author":"Savi","year":"2001","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814002412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814002412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:07:25Z","timestamp":1746191245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814002412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0049384814002412"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.04.027","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}